​

Trinity Biotech (TRIB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

TRIB Stock Rating

Trinity Biotech stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

TRIB Price Target Upside V Benchmarks

TypeNameUpside
StockTrinity Biotech-
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks6.76%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.02$1.02$1.02
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25------
Aug, 25------
Jul, 25------
Jun, 25------
Apr, 25------
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.44$0.21$-6.08$-15.69---
Avg Forecast$2.70$2.30$-3.55$-2.95$-1.74$-0.90$-0.49
High Forecast$2.70$2.30$-3.55$-2.95$-1.74$-0.90$-0.49
Low Forecast$2.70$2.30$-3.55$-2.95$-1.74$-0.90$-0.49
Surprise %-153.33%-90.87%71.27%431.86%---

Revenue Forecast

$55M $65M $75M $85M $95M $105M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$101.98M$92.97M$74.78M$56.83M---
Avg Forecast$97.22M$97.44M$74.74M$58.23M$62.20M$68.50M$77.50M
High Forecast$97.22M$97.44M$74.74M$58.23M$62.20M$68.50M$77.50M
Low Forecast$97.22M$97.44M$74.74M$58.23M$62.20M$68.50M$77.50M
Surprise %4.90%-4.59%0.05%-2.40%---

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-6.01M$875.00K$-41.00M$-24.02M---
Avg Forecast$24.03M$3.89M$4.42M$5.03M$-266.39M$-137.79M$-75.02M
High Forecast$24.03M$7.72M$8.66M$9.74M$-266.39M$-137.79M$-75.02M
Low Forecast$24.03M$50.82K$168.61K$328.05K$-266.39M$-137.79M$-75.02M
Surprise %-125.02%-77.48%-1028.68%-577.04%---

TRIB Forecast FAQ

Is Trinity Biotech stock a buy?

Trinity Biotech stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Trinity Biotech is a favorable investment for most analysts.

What is Trinity Biotech's price target?

Trinity Biotech's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.02.

How does Trinity Biotech stock forecast compare to its benchmarks?

Trinity Biotech's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (6.76%).

What is Trinity Biotech’s EPS forecast?

Trinity Biotech's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.74, marking a -88.91% decrease from the reported $-15.69 in 2023. Estimates for the following years are $-0.9 in 2025, and $-0.49 in 2026.

What is Trinity Biotech’s revenue forecast?

Trinity Biotech's average annual revenue forecast for its fiscal year ending in December 2024 is $62.2M, reflecting a 9.44% increase from the reported $56.83M in 2023. The forecast for 2025 is $68.5M, and $77.5M for 2026.

What is Trinity Biotech’s net income forecast?

Trinity Biotech's net income forecast for the fiscal year ending in December 2024 stands at $-266M, representing an 1009.14% increase from the reported $-24.018M in 2023. Projections indicate $-138M in 2025, and $-75.019M in 2026.